"Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The company’s lead candidate, MGL-3196, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist in clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and familial dyslipidemias/hypercholesterolemias, among other related indications. [source: madrigalpharma.com]"
MDGL has been up well over 600% the past year!
Besides discussion and new on MDGL, discussion of other pharmaceudicals working on NASH is welcome. Some of these are VKTX, GLMD, ICPT , GNFTF , GILD, and PFE (for which there is a thread here at SI).
|
